Metabolism & CYP450 — Metabolism concepts (Phase I/II,...

SECTION 1

Historical Context & Motivation

The study of how the body chemically transforms xenobiotics—foreign substances including drugs—has been central to pharmacology for well over a century. Early clinicians observed that the same dose of a drug could produce wildly different effects in different patients, and that drugs did not persist in the body indefinitely. These observations pointed toward an active biological process of chemical modification, now known as drug metabolism or biotransformation. Understanding this process is essential for predicting drug efficacy, toxicity, duration of action, and the potential for dangerous drug–drug interactions.

The discovery that the liver serves as the principal organ of drug metabolism was followed by decades of biochemical work that ultimately identified the cytochrome P450 (CYP450) superfamily of enzymes as the dominant catalysts of Phase I oxidative metabolism. Simultaneously, researchers elucidated the conjugation reactions of Phase II metabolism, which attach polar moieties to drugs or their Phase I metabolites, facilitating renal or biliary excretion. Together, these pathways constitute the biochemical machinery that determines how long a drug remains active in the body.

1842

First Biotransformation Described

Alexander Ure demonstrated that hippuric acid appeared in urine after ingestion of benzoic acid, providing one of the earliest documented examples of a conjugation (Phase II) reaction in humans.

1947

Williams' Phase Classification

R.T. Williams published a landmark textbook proposing the classification of drug metabolism into Phase I (functionalization) and Phase II (conjugation) reactions, a framework still used today.

1958

Discovery of Cytochrome P450

Martin Klingenberg discovered a carbon monoxide–binding pigment in liver microsomes that absorbed light at 450 nm, naming it P450 ('pigment at 450 nm'). This protein would later be identified as a superfamily of heme-containing monooxygenases.

1980s

Molecular Cloning of CYP Isoforms

Advances in molecular biology enabled the cloning and characterization of individual CYP isoforms (e.g., CYP3A4, CYP2D6), revealing that a small number of enzymes are responsible for metabolizing the vast majority of clinically used drugs.

2000s–Present

Pharmacogenomics & Personalized Medicine

Genomic studies revealed widespread genetic polymorphisms in CYP genes, leading to the identification of poor, intermediate, extensive, and ultra-rapid metabolizer phenotypes—ushering in the era of pharmacogenomics-guided prescribing.

The fundamental question that this area of pharmacology addresses is deceptively simple: How does the body chemically alter drugs, and why does this matter clinically? The answer involves a sophisticated enzymatic system that evolved to detoxify endogenous waste products and dietary xenobiotics, but which modern medicine must navigate every time a prescription is written.

SECTION 2

Core Principles of Drug Metabolism

Drug metabolism is governed by several foundational principles that link chemistry, physiology, and clinical pharmacology. At its core, biotransformation serves to convert lipophilic (fat-soluble) parent compounds into more hydrophilic (water-soluble) metabolites that can be eliminated by the kidneys or bile. Without this process, many lipophilic drugs would be passively reabsorbed from the renal tubule and remain in the body for extraordinarily long periods.

Phase I — Functionalization

Phase I reactions introduce or unmask a functional group (−OH, −NH₂, −SH, −COOH) via oxidation, reduction, or hydrolysis. The resulting metabolite is slightly more polar but may still retain pharmacological activity—or even gain toxicity.

Phase II — Conjugation

Phase II reactions attach a large, highly polar endogenous molecule (glucuronic acid, sulfate, glutathione, acetyl, methyl, or glycine) to the drug or its Phase I metabolite via transferase enzymes. Conjugates are typically pharmacologically inactive and readily excreted.

First-Pass Metabolism

Orally administered drugs absorbed from the GI tract are delivered directly to the liver via the portal circulation. Extensive hepatic metabolism before reaching systemic circulation—the first-pass effect—can dramatically reduce a drug's oral bioavailability.

Enzyme Induction & Inhibition

CYP450 enzymes can be induced (increased expression) or inhibited (decreased activity) by co-administered drugs, foods, or herbal products, leading to clinically significant drug–drug interactions that alter plasma levels.

Genetic Polymorphism

Variations in CYP450 genes produce distinct metabolizer phenotypes—poor, intermediate, extensive (normal), and ultra-rapid—which explain much of the interindividual variability in drug response and toxicity risk.

✦ KEY TAKEAWAY

Think of drug metabolism like a two-stage dishwasher cycle. Phase I is the scrubbing stage—it exposes or creates a 'handle' (functional group) on the drug molecule, like loosening baked-on food. Phase II is the rinse stage—it attaches a large, water-loving tag that makes the molecule slippery enough to be washed out of the body through urine or bile. Some drugs need both cycles; others can skip straight to the rinse because they already have an exposed handle.

SECTION 3

Visual Overview of Drug Biotransformation

The following diagram illustrates the overall pathway of drug metabolism from the lipophilic parent compound through Phase I functionalization and Phase II conjugation, culminating in renal or biliary excretion of the hydrophilic metabolite. Note that some drugs undergo Phase II conjugation directly if they already possess a suitable functional group, while others require sequential Phase I and Phase II processing.

The diagram traces the journey of a lipophilic parent drug through Phase I functionalization (oxidation, reduction, or hydrolysis catalyzed by CYP450 enzymes) and Phase II conjugation (glucuronidation, sulfation, glutathione conjugation, acetylation, or methylation). The dashed pink arrow indicates that drugs with pre-existing functional groups may bypass Phase I entirely.

As depicted in the diagram, the overall goal of biotransformation is the progressive increase in water solubility. The parent drug, which is typically lipophilic enough to cross cell membranes and reach its target, is first modified by Phase I enzymes to expose or introduce a reactive functional group. This metabolite may retain partial pharmacological activity (and in some cases, as with prodrugs, the Phase I metabolite is the actual active compound). The Phase I metabolite then serves as a substrate for Phase II transferase enzymes, which attach a bulky, polar conjugate that dramatically increases molecular weight and water solubility, effectively terminating pharmacological activity and marking the molecule for excretion.

SECTION 4

The CYP450 Catalytic Cycle & Kinetic Framework

The cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases located primarily in the smooth endoplasmic reticulum of hepatocytes, although they are also expressed in the intestinal epithelium, lungs, kidneys, and brain. The name 'P450' derives from the characteristic spectral absorption peak at 450 nm when the reduced heme iron binds carbon monoxide. These enzymes catalyze the general reaction in which one atom of molecular oxygen is inserted into the substrate while the other is reduced to water, using NADPH as the electron donor.

GENERAL CYP450 MONOOXYGENASE REACTION

RH + O₂ + NADPH + H⁺ → ROH + H₂O + NADP⁺

Where RH = the drug substrate, ROH = the hydroxylated metabolite, NADPH = the electron donor (reduced nicotinamide adenine dinucleotide phosphate), and O₂ = molecular oxygen. One oxygen atom is incorporated into the substrate; the other is reduced to water.

The enzymatic metabolism of drugs follows Michaelis-Menten kinetics, which describes the relationship between substrate concentration and the rate of enzymatic reaction. At low drug concentrations, metabolism is approximately first-order (rate proportional to concentration), while at high concentrations the enzymes become saturated and metabolism becomes zero-order (rate is constant regardless of concentration). This saturation kinetics has profound clinical implications.

MICHAELIS-MENTEN EQUATION

v = (V_max × [S]) / (K_m + [S])

v = rate of metabolism, V_max = maximum rate when all enzyme is saturated, [S] = substrate (drug) concentration, K_m = Michaelis constant (the substrate concentration at which v = V_max/2). A low K_m indicates high enzyme affinity for the substrate.

HEPATIC EXTRACTION RATIO

E = (C_in − C_out) / C_in

E = extraction ratio (0 to 1), C_in = drug concentration entering the liver (portal vein), C_out = drug concentration leaving the liver (hepatic vein). Drugs with E > 0.7 (e.g., morphine, propranolol) are termed 'high-extraction' drugs and exhibit extensive first-pass metabolism. Oral bioavailability ≈ 1 − E for such drugs.

⚕️ Clinical Pearl

When [S] ≪ K_m, the Michaelis-Menten equation simplifies to v ≈ (V_max/K_m) × [S], yielding first-order kinetics. Most drugs operate in this range at therapeutic doses. However, certain drugs like phenytoin and ethanol readily saturate their metabolizing enzymes, shifting to zero-order (capacity-limited) kinetics where small dose increases produce disproportionately large rises in plasma concentration—a clinically dangerous scenario.

SECTION 5

Major CYP450 Isoforms & Their Clinical Significance

Although over 50 CYP isoforms have been identified in humans, only a handful are responsible for the metabolism of the vast majority of clinically used drugs. The CYP naming convention uses a number for the family (≥40% amino acid homology), a letter for the subfamily (≥55% homology), and a final number for the individual isoform. For example, CYP3A4 belongs to family 3, subfamily A, isoform 4. Understanding the substrate specificities and susceptibility to induction or inhibition of the major isoforms is essential for predicting and preventing drug–drug interactions.

Horizontal bar chart (left) showing the approximate percentage of clinically used drugs metabolized by each major CYP450 isoform. The reference panel (right) lists key substrates, inhibitors, and inducers for each isoform. Note that CYP3A4/5 alone handles roughly half of all drug metabolism, making it the single most clinically important isoform.

Major CYP450 isoforms with approximate contribution to drug metabolism, representative substrates, inhibitors, and inducers

CYP Isoform	% Drugs Metabolized	Notable Substrates	Major Inhibitors	Major Inducers
CYP3A4/5	~50%	Atorvastatin, nifedipine, midazolam, ritonavir, cyclosporine	Ketoconazole, itraconazole, ritonavir, grapefruit juice	Rifampin, carbamazepine, phenytoin, St. John's wort
CYP2D6	~25%	Codeine, tamoxifen, metoprolol, haloperidol, fluoxetine	Fluoxetine, paroxetine, bupropion, quinidine	Not significantly inducible
CYP2C9	~10%	Warfarin (S-enantiomer), phenytoin, ibuprofen, losartan	Fluconazole, amiodarone, metronidazole	Rifampin
CYP2C19	~5%	Clopidogrel (prodrug activation), omeprazole, diazepam	Omeprazole, fluvoxamine, fluoxetine	Rifampin
CYP1A2	~5%	Caffeine, theophylline, clozapine, tizanidine	Ciprofloxacin, fluvoxamine	Smoking (PAHs), charbroiled meat, cruciferous vegetables
CYP2E1	~3%	Ethanol, acetaminophen (to NAPQI), enflurane	Disulfiram	Chronic ethanol use, isoniazid

SECTION 6

Worked Example: Predicting a CYP-Mediated Drug Interaction

Consider the following clinical scenario: a 62-year-old male patient is on a stable dose of warfarin (a CYP2C9 substrate) for atrial fibrillation anticoagulation. His INR has been consistently in the therapeutic range (2.0–3.0). He develops a fungal infection and is prescribed fluconazole (a potent CYP2C9 inhibitor). Predict what will happen to his warfarin plasma levels and clinical response.

Warfarin–Fluconazole Interaction Analysis

Step 1 — Identify the Metabolic PathwayWarfarin exists as a racemic mixture. The more potent S-warfarin enantiomer is metabolized primarily by CYP2C9, with minor contributions from CYP3A4 for the R-enantiomer. The clearance of S-warfarin is therefore highly dependent on CYP2C9 activity.

Primary pathway: S-warfarin → CYP2C9 → 7-hydroxywarfarin (inactive metabolite)

Step 2 — Characterize the Interacting DrugFluconazole is a potent competitive inhibitor of CYP2C9. By occupying the active site of CYP2C9, fluconazole prevents S-warfarin from being metabolized. This effectively increases the apparent K_m of the enzyme for warfarin without changing V_max (classic competitive inhibition).

Fluconazole = CYP2C9 inhibitor → decreased warfarin metabolism

Step 3 — Predict the Pharmacokinetic ConsequenceWith CYP2C9 inhibited, the clearance (CL) of S-warfarin decreases. Since at steady state, average plasma concentration (C_ss) = Dose / (CL × τ), where τ is the dosing interval, a decrease in CL with unchanged dosing will lead to a proportional increase in steady-state plasma warfarin concentration. Additionally, the half-life (t_½) will increase because t_½ = 0.693 × V_d / CL.

↓ CL → ↑ C_ss and ↑ t_½

Step 4 — Predict the Clinical OutcomeElevated warfarin plasma levels produce an exaggerated anticoagulant effect, reflected as a supratherapeutic INR (potentially INR > 4.0). This places the patient at significantly increased risk for serious bleeding complications, including intracranial hemorrhage. Clinical management requires either empiric warfarin dose reduction (typically 25–50%) when initiating fluconazole, with frequent INR monitoring.

↑ Warfarin levels → ↑ INR → ↑ Bleeding risk. Action: reduce warfarin dose and monitor INR closely.

SECTION 7

Phase I vs. Phase II: Comparative Analysis

While Phase I and Phase II reactions are often presented sequentially, it is important to appreciate their distinct biochemical logic, different enzyme families, and contrasting clinical implications. Some drugs undergo only Phase I metabolism (if the resulting metabolite is already sufficiently hydrophilic), some undergo only Phase II (if the parent drug already bears a suitable functional group), and many undergo both in sequence. The following comparison highlights the key distinctions.

Comparison of Phase I and Phase II drug metabolism characteristics

Feature	Phase I (Functionalization)	Phase II (Conjugation)
Primary reaction types	Oxidation, reduction, hydrolysis	Glucuronidation, sulfation, acetylation, methylation, glutathione conjugation, amino acid conjugation
Key enzyme families	CYP450, FMO (flavin monooxygenases), esterases, epoxide hydrolase	UGT (UDP-glucuronosyltransferases), SULT (sulfotransferases), NAT (N-acetyltransferases), GST (glutathione-S-transferases), TPMT (thiopurine methyltransferase)
Cofactors required	NADPH, O₂	UDP-glucuronic acid, PAPS, acetyl-CoA, SAM, glutathione, glycine
Effect on molecular weight	Minimal change (addition of −OH, −NH₂)	Significant increase (addition of glucuronic acid ≈ 176 Da, glutathione ≈ 307 Da)
Effect on polarity	Slight increase in hydrophilicity	Major increase in hydrophilicity; products are highly water-soluble
Metabolite activity	May be active, inactive, or toxic (e.g., NAPQI from acetaminophen)	Usually pharmacologically inactive (notable exception: morphine-6-glucuronide is active)
Susceptibility to DDIs	Highly susceptible; CYP450 enzymes are readily induced/inhibited	Less susceptible overall, though UGT induction (e.g., by rifampin) and competitive inhibition can occur
Genetic polymorphism impact	High (CYP2D6, CYP2C19, CYP2C9 show clinically significant polymorphisms)	Moderate (NAT2 slow acetylators → isoniazid toxicity; UGT1A1*28 → Gilbert syndrome, irinotecan toxicity)

✦ KEY TAKEAWAY

Phase I and Phase II metabolism function as complementary systems, not simply sequential ones. Phase I reactions expose or create chemical 'hooks' on the drug molecule, while Phase II reactions use these hooks to attach water-soluble 'tags.' Consider it analogous to preparing a package for shipping: Phase I is addressing and labeling the package (making it identifiable), while Phase II is applying the postage (making it ready for transport and elimination). Some packages arrive pre-labeled and skip straight to postage.

SECTION 8

Connection to Pharmacogenomics & Advanced Therapeutics

The foundational concepts of Phase I and Phase II metabolism provide the biochemical framework upon which the rapidly advancing field of pharmacogenomics is built. Genetic polymorphisms in CYP450 genes produce distinct metabolizer phenotypes that have direct clinical consequences. A patient who is a CYP2D6 poor metabolizer cannot convert codeine to morphine (its active metabolite) and will experience no analgesic effect, while a CYP2D6 ultra-rapid metabolizer may produce dangerously high morphine levels from a standard codeine dose. These concepts extend naturally into personalized prescribing and pharmacogenomic testing.

Bridge from foundational metabolism concepts to pharmacogenomic applications

Concept Level	Foundational (This Lesson)	Advanced (Pharmacogenomics)
Enzyme variability	CYP isoforms have different substrate specificities; induction/inhibition alter activity	Specific SNPs (e.g., CYP2D64, CYP2C192) ablate enzyme function; star-allele nomenclature predicts phenotype
Drug interactions	Co-administration of inhibitors/inducers alters drug clearance	Phenoconversion: drug inhibitors convert a genotypic extensive metabolizer into a phenotypic poor metabolizer
Prodrug activation	Phase I metabolism converts prodrugs (e.g., clopidogrel) to active form	CYP2C19 poor metabolizers have reduced clopidogrel activation; FDA boxed warning recommends alternative antiplatelet therapy
Toxic metabolite formation	CYP2E1 converts acetaminophen to hepatotoxic NAPQI; glutathione conjugation detoxifies it	CYP2E1 induction by chronic ethanol predisposes alcoholic patients to APAP hepatotoxicity at lower doses
Clinical application	Check drug interaction databases; adjust doses with known inhibitors/inducers	Preemptive pharmacogenomic testing (e.g., CPIC guidelines) to select drugs and doses based on genotype before prescribing

As you progress in pharmacology, you will encounter increasingly sophisticated applications of these metabolic principles. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published evidence-based guidelines for genotype-guided prescribing of drugs such as clopidogrel (CYP2C19), codeine and tramadol (CYP2D6), warfarin (CYP2C9 and VKORC1), and fluoropyrimidines (DPYD). Understanding the CYP450 system presented in this lesson is the prerequisite for interpreting these guidelines and applying them in clinical practice.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

Explain the fundamental difference in biochemical purpose between Phase I and Phase II drug metabolism reactions. Why are both phases generally necessary to eliminate a highly lipophilic drug from the body?

PROBLEM 2 — BASIC CALCULATION

A drug has a hepatic extraction ratio (E) of 0.85. Calculate the approximate oral bioavailability (F) attributable to first-pass metabolism alone (assume complete GI absorption). If the IV dose needed for therapeutic effect is 10 mg, what oral dose would be required to achieve an equivalent systemic drug level?

PROBLEM 3 — INTERMEDIATE

A patient stabilized on theophylline (a CYP1A2 substrate with a narrow therapeutic index) quits smoking. Predict the pharmacokinetic and clinical consequences, and explain the mechanism underlying the expected change.

PROBLEM 4 — APPLIED

A chronic alcoholic patient presents with liver injury after taking what should be a safe dose of acetaminophen (3 g/day). Using your knowledge of CYP2E1 and Phase II glutathione conjugation, explain the pathophysiological mechanism of acetaminophen hepatotoxicity in this patient.

PROBLEM 5 — CRITICAL THINKING

Clopidogrel is a prodrug that requires CYP2C19-mediated bioactivation. A patient is genotyped as a CYP2C19 poor metabolizer (CYP2C19*2/*2). Simultaneously, this patient is started on omeprazole (a CYP2C19 inhibitor) for gastric protection. Analyze both the pharmacogenomic and drug interaction implications for clopidogrel efficacy. What therapeutic recommendations would you make, and why?

SUMMARY

Lesson Summary

Drug metabolism, or biotransformation, converts lipophilic parent drugs into hydrophilic metabolites that can be excreted renally or via bile. Phase I reactions (oxidation, reduction, hydrolysis) introduce or unmask polar functional groups, primarily through the cytochrome P450 (CYP450) superfamily of heme-containing monooxygenases located in hepatic smooth endoplasmic reticulum. Phase II reactions attach bulky, polar conjugates (glucuronic acid, sulfate, glutathione, acetyl groups) via transferase enzymes, dramatically increasing water solubility and typically abolishing pharmacological activity. The overall reaction follows Michaelis-Menten kinetics, with most drugs cleared by first-order kinetics at therapeutic concentrations.

Among the CYP450 isoforms, CYP3A4 metabolizes approximately 50% of clinically used drugs, followed by CYP2D6 (~25%), CYP2C9 (~10%), and CYP2C19 and CYP1A2 (~5% each). Enzyme induction increases CYP expression and accelerates drug clearance, while enzyme inhibition decreases clearance and raises plasma drug levels—forming the basis of most clinically significant drug–drug interactions. Genetic polymorphisms in CYP genes produce poor, intermediate, extensive, and ultra-rapid metabolizer phenotypes that profoundly influence drug efficacy, toxicity, and dosing requirements—connecting these foundational concepts to the emerging field of pharmacogenomics-guided prescribing.